Target Entity: Curexis Ventures Private Limited

Type of Deal: Subscription to rights issue in wholly-owned subsidiary

Stake/Capacity: Acquisition of 20,20,000 equity shares. Post-acquisition, Curexis Ventures Private Limited continues to remain as the wholly-owned subsidiary of the company.

Deal Value: ₹4,04,00,000.00 (₹4.04 crore) at ₹20.00 per equity share (including premium of ₹10.00 per equity share)

Funding Source: Cash consideration

Financial Impact:

  • The investment will be utilized by Curexis Ventures for repayment of outstanding unsecured loan availed from Zota Health Care Limited
  • Results in reduction of Group's total outstanding debt on a consolidated basis
  • Improves overall net worth of the Group
  • No change in subsidiary status - remains wholly-owned

Timeline: Transaction completed on October 01, 2026

Strategic Rationale:

  • The rights issue subscription enables the subsidiary to repay its debt to the parent company
  • Strengthens the subsidiary's capital structure
  • Reduces consolidated group leverage
  • Maintains operational continuity of the retail pharmacy business under the 'SKIA' brand

Approval Status: Transaction completed on October 01, 2026

Reference Regulation: SEBI Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Additional Company Information:

Target Company Background:

  • Incorporated: February 25, 2025
  • Business: Drug manufacturing, development, and marketing company operating retail pharmacy stores under the 'SKIA' brand
  • Product Range: Pharmaceutical, Nutraceutical, Cosmetic, Ayurvedic and OTC products
  • Financial Performance:
  • FY 2025-26: Turnover ₹1.18 lakh
  • FY 2024-25: Not available
  • FY 2023-24: Not available
  • Current Paid-up Share Capital: ₹101 lakh

Transaction Details:

  • Not a related party transaction
  • Arm's length basis
  • Promoter/promoter group/group companies have no interest in the subsidiary